A newly synthesized oxadiazol-3-one derivative (5b) demonstrates 20-fold greater calcium channel blocking activity in vitro compared to diltiazem.
Answers are grounded in this paper and cite their sources.
Warrants further preclinical investigation as a calcium channel blocker; leaves open in vivo efficacy versus diltiazem.
In the framework of the continuing interest of this research group in the use of 8-aryl-8-hydroxy-8H-[1,4]thiazino[3,4-c][1,2,4]oxadiazol-3-ones (1) as calcium entry blockers, a number of acetals were synthesized and assayed "in vitro". All of them are structurally related to diltiazem and pyrrolobenzothiazines. The effect on the biological profile was measured by functional assays for a wide variety of acetal residues: saturated linear and branched chains, short and long unsaturated E and/or Z chains as well as benzyl and methylcyclohexyl residues. From selective assays on the most active derivative (5b) (EC(50) = 0.04 microM), which is 20 times more active than diltiazem (EC(50) = 0.79 microM), a muscarinic or adenosinic mechanism of action was excluded. A 3D QSAR model was obtained and validated with homologous literature data, and a virtual receptor scheme was derived for the unknown binding site. The following pharmacophoric features favorably affect the potency: one positively charged center, three lipophilic groups, and two hydrogen-bonding acceptor groups.
No takes yet. Share an insight, caveat, or question.
Budriesi et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: